Safety, efficacy, and drug survival of the infliximab biosimilar <scp>CT‐P13</scp> in post‐marketing surveillance of Japanese patients with psoriasis-Reference-Cited by-同舟云学术

Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis

Author:

Morita Akimichi¹^ORCID,Nishikawa Kiyohiro²³^ORCID,Yamada Fumika²,Yamanaka Keiichi⁴,Nakajima Hideki⁵,Ohtsuki Mamitaro⁶

Affiliation:

1. Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

2. Quality and Pharmacovigilance Division Pharmaceuticals Group, Nippon Kayaku Co., Ltd. Tokyo Japan

3. Asajes Ventures Tokyo Japan

4. Department of Dermatology Mie University Graduate School of Medicine Tsu Japan

5. Department of Dermatology Kochi Medical School, Kochi University Nankoku Japan

6. Department of Dermatology Jichi Medical University Shimotsuke Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

Reference32 articles.

1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis;Sbidian E;Cochrane Database Syst Rev,2021

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Biosimilars in Dermatology Review;Journal of Psoriasis and Psoriatic Arthritis;2023-11-03